Latest Conference Articles

Heather Wakelee, MD, associate professor of medicine (oncology) at the Stanford University Medical Center, discussed the latest therapeutic developments in EGFR-mutant non-small cell lung cancer.

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; associate director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center, discusses immunotherapy combinations that have potential in non-small cell lung cancer (NSCLC).

Vassiliki A. Papadimitrakopoulou, MD, shares insight on how the lung cancer paradigm continues to evolve with the identification of targetable driver mutations, the challenges that remain, and the ongoing clinical trial efforts designed to better reach patients and improve their outcomes.

Checkpoint inhibition following chemoradiation has shown remarkable successes for patients with locally advanced non–small cell lung cancer, after more than 2 decades without major advances.

The past year has witnessed an explosion in immunotherapy combinations for patients with lung cancer, accompanied by a growing knowledge of biomarkers such as PD-L1 and tumor mutation burden; however, an exact standard of care remains elusive.

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care

Karen Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, medical director, Clinical Research Operations, professor, Department of Medical Oncology & Therapeutics Research, thoracic oncologist, discusses current and emerging therapeutic strategies to target MET in non-small cell lung cancer.

Molecular pathologists have helped to advance translational research significantly for lung cancer over the past 10 years; nowhere is that more obvious than in EGFR-mutant non-small cell lung cancer.

Immunotherapy should be given as a tailored, not blanket, treatment approach, especially for patients with lung cancer, according to Giorgio Scagliotti, MD, PhD.

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the practice-changing data from the PACIFIC trial, which evaluated durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.

Lyudmila A. Bazhenova, MD, medical oncologist professor of medicine, University of California, San Diego, discusses the prevalence of NTRK mutations in non–small cell lung cancer.

Several novel targeted therapies are emerging for a growing number of driver mutations in lung cancer, with multiple targeted agents now confirmed standards of care.

Gabriela S. Hobbs, MD, clinical director, Leukemia Service, assistant in medicine, Massachusetts General Hospital, discusses the updated NCCN guidelines in chronic myeloid leukemia (CML).

Danielle Marie Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment landscape for patients with high-risk chronic lymphocytic leukemia (CLL).

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses emerging agents in relapsed/refractory multiple myeloma.

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses brentuximab vedotin (Adcetris) in cutaneous T-cell lymphoma.

Steven M. Ansell, MD, PhD, discusses the efficacy of PD-L1 blockade in Hodgkin lymphoma, patient treatment that has encouraged him to look for deeper solutions, alternative drug combinations that appear to be making headway, and potential avenues of discovery for the future.

Sagar Lonial, MD, discusses optimal sequencing techniques for patients with relapsed/refractory myeloma.

United States’ versus European perspectives on bleomycin in chemotherapy combinations for advanced Hodgkin lymphoma, along with the value of interim positron emission tomography, were discussed at the 2018 Pan Pacific Lymphoma Conference.

Jacqueline D. Barrientos, MD, MS, discusses the current treatment landscape for CLL, highlights some of the biggest challenges for physicians, and gives her insight on how to move forward in the field.

Major advancements in immunotherapy are at the forefront of treatment for patients with acute lymphoblastic leukemia.

Sham Mailankody, MBBS, discusses current treatment options and shifting preferences, especially toward triplet combinations, as well as emerging immunotherapy treatment options in multiple myeloma.

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in adult patients with Burkitt lymphoma.

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the antibody drug conjugate polatuzumab vedotin in lymphoma.

A retrospective study of patients with Hodgkin lymphoma found high rates of sequelae including pulmonary events and cardiovascular disease following frontline treatment with chemotherapy including bleomycin.

Steven M. Horwitz, MD, discusses the best strategy for the treatment of CD30-positive peripheral T-cell lymphomas.

Sarah Holstein, MD, PhD, discusses new approaches to induction therapy for patients with myeloma.

David G. Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses updates with CAR T-cell therapy in non-Hodgkin lymphoma.

Julie M. Vose, MD, MBA, professor, internal medicine, chief, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the importance of genomic analysis in patients with non-Hodgkin lymphoma.

Combinations of novel drugs in lymphomas have the potential to overcome resistance to therapy but come with sometimes unexpected adverse events that demand careful monitoring.